Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Study Identifies Two Measures of Tumor Burden for Risk Stratification of Patients With Hodgkin...

The presence of bulky disease is commonly used as one factor in categorizing patients with early-stage Hodgkin lymphoma (HL) as having either favorable or...
WIB_icon

Examining Infection Risk in Patients Treated With Anti-CD19 CAR T-Cell Therapies

Management of the toxicities commonly associated with chimeric antigen receptor (CAR) T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity, can require stays in...
WIB_icon

Is Radiotherapy Necessary for Treating DLBCL With R-CHOP?

The combination of involved-field radiotherapy (RT) and chemotherapy has been considered a standard treatment for patients with early-stage diffuse large B-cell lymphoma (DLCBL), but...

Clinical Trials Review Confirms Poor Outcomes for Patients With Refractory NHL

In an analysis of patient-level data from four large trial cohorts, researchers reported that patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)...

TP53 Mutations Identify Patients With “Highly Aggressive” Mantle Cell Lymphoma

Patients with TP53-mutated mantle cell lymphoma (MCL) have poor overall survival (OS), compared with patients without the mutation. In an analysis of two trials...

Comparing Brentuximab Vedotin–Based Frontline Regimens for Hodgkin Lymphoma in Older Patients

The combinations of brentuximab vedotin (BV) and dacarbazine or BV and bendamustine both led to high objective response rates (ORR) in older patients with...
WIB_icon

Predicting the Risk and Severity of Cytokine Release Syndrome in Patients Receiving CAR T-Cell...

While treatment with CD19-directed chimeric antigen receptor (CAR) T cells has demonstrated impressive response rates of over 80% in select patients with B-cell malignancies,...
WIB_icon

Adding Rituximab to Corticosteroids and Cyclosporine A in Patients With cGVHD Improves ORR

Standard firstline treatment for chronic graft-versus-host disease (cGVHD) includes corticosteroids and cyclosporine A, but disease control often requires long-term immunosuppressive treatment, which impairs patients’...
WIB_icon

Examining Ibrutinib as Secondline Therapy for Chronic Graft-Versus-Host Disease

On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved the Bruton tyrosine kinase inhibitor ibrutinib as a secondline treatment for adult...
WIB_icon

Early Study Shows Venetoclax Is Active in Patients With Relapsed/Refractory Myeloma and t(11;14)

Venetoclax, an oral BCL2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of chronic lymphocytic leukemia, may be a treatment...
Advertisement

Current Issue

December 2017, Volume 3, Issue 14

This issue features physicians' insights on gun control, the use of cannabis for symptom relief, and more.